Carmen García-Gómez

Carmen García-Gómez

Auto-generated profile, based on publicly available information

Carmen García-Gómez

Division of Rheumatology, Consorci Sanitari de Terrassa, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2007 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
BBBerta Bernad
Berta Bernad
DRDaniel Roig-Vilaseca
Daniel Roig-Vilaseca
CGCarmen García-Gómez
Carmen García-Gómez
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
JVJosé Valverde
José Valverde

18 August 2008 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
CGC. García‐Gómez
C. García‐Gómez
JNJ. M. Nolla
J. M. Nolla
JVJ. Valverde
J. Valverde
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
ECEmili Corbella
Emili Corbella
Xavier PintóXavier Pintó
Xavier Pintó

1 January 2014 in World Journal of Orthopedics
Verified
Journal Article
Open access
CGCarmen García-Gómez
Carmen García-Gómez
Inflammation, lipid metabolism and cardiovascular risk in rheumatoid arthritis: A qualitative relationship?

1 May 2017 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
CGCarmen García-Gómez
Carmen García-Gómez
MMMaria A. Martín-Martínez
Maria A. Martín-Martínez
Santos CastañedaSantos Castañeda
Santos Castañeda
FSFernando Sanchez-Alonso
Fernando Sanchez-Alonso
MUMiren Uriarte-Ecenarro
Miren Uriarte-Ecenarro
JMJosé A. Miranda-Filloy
José A. Miranda-Filloy
Plasma concentrations of lipoprotein (a) (Lp(a)), a lipoprotein with atherogenic and thrombogenic properties, have a strong genetic basis, although high concentrations of Lp(a) have also been reported in the context of inflammation, as in rheumatoid arthritis (RA). Few studies evaluate the impact of biologic therapies (BT) on Lp(a) in RA, taking into account that with these new therapies a better control of inflammation is achieved. The aim of the study was to evaluate the plasma concentrations of Lp(a) in Spanish RA patients on BT attending rheumatology outpatient clinics. Baseline analysis of the CARdiovascular in rheuMAtology project, a 10-year prospective study, evaluating the risk of cardiovascular events in RA and other forms of inflammatory arthritis. RA patients were classified according to treatment: no biologic, anti-tumor necrosis factor, anti-interleukin-6 receptor tocilizumab (TCZ), and other biologic (rituximab or abatacept). A model of linear multivariate regression was built in which the dependent variable was Lp(a) concentration and the explanatory variable was BT. The model was adjusted for confounding factors. Seven hundred and seventy-five RA patients were analyzed. Plasma concentrations of total cholesterol and triglyceride were significantly higher in TCZ-treated patients. Nevertheless, no significant difference in the atherogenic index between TCZ-treated patients and patients without BT was found. After adjusting for confounding factors, patients with BT had lower concentrations of Lp(a) than those without BT; however, only TCZ-treated patients achieved statistically significant differences (β: -0.303, 95% confidence interval: -0.558 to -0.047; P = .02). RA patients treated with TCZ show lower plasma concentrations of Lp(a) compared with patients without BT.

15 April 2009 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
CGCarmen García-Gómez
Carmen García-Gómez
JNJoan M. Nolla
Joan M. Nolla
JVJosep Valverde
Josep Valverde
JGJuan A. Gómez-Gerique
Juan A. Gómez-Gerique
MCMaría J. Castro
María J. Castro
Xavier PintóXavier Pintó
Xavier Pintó
Objective. Patients with rheumatoid arthritis (RA) have an increased cardiovascular risk not completely explained by traditional cardiovascular risk factors. If the proatherogenic lipid profile observed in active and untreated RA improves by effectively treating RA without the use of a lipid-lowering agent, other nonconventional cardiovascular lipid risk factors may be implicated. We evaluated conventional lipid risk factors and lipoprotein(a) in treated patients with RA.

1 January 2020 in Clínica e Investigación en Arteriosclerosis (English Edition)
Verified
Journal Article
Closed access
MGMaría Carmen García-Gómez
María Carmen García-Gómez
Gemma VilahurGemma Vilahur
Gemma Vilahur